



SDI FINAL EVALUATION FORM 1.1

PART 1:

Journal Name:	British Journal of Medicine and Medical Research
Manuscript Number:	2013_BJMMR_6435
Title of the Manuscript:	FACTORS THAT INFLUENCE COMPLIANCE WITH ANNUAL IVERMECTIN TREATMENT AND WILLINGNESS OF INDIVIDUALS TO CONTINUE WITH THE TREATMENT IN ABIA STATE, NIGERIA

PART 2:

FINAL EVALUATOR'S comments on revised paper (if any)	Authors' response to final evaluator's comments
<p>There continue to be many grammatical errors that would need to be addressed before publishing. I have noted some of these directly in the paper.</p> <p>One statistic is very old: many times the 33 million people noted in the paper receive ivermectin treatment each year.</p> <p>Abbreviation "FDG" is not defined.</p> <p>This sentence does not make sense: "(16) also recommended health education as one of the main strategies towards improving treatment." (sic)</p> <p>This newly added item needs clarification: "Biannual treatment is also recommended to enable those who could not be treated during the first treatment period to be treated later." Does this mean biannual treatment for everyone? Or a catch up round only for those who missed the previous round? There is a big difference.</p> <p>This observation does not seem to be supported by the study results: "Economic empowerment of people blinded by onchocerciasis should be emphasized. Such individuals should be encouraged to learn crafts thus reducing the number of beggars on our streets." Economic empowerment is important for those blinded, to be sure, but how does the evidence show that it will boost compliance with treatment?</p>	

Reviewer Details:

Name:	Ken Gustavsen
Department, University & Country	Merck and Co. Inc. in Whitehouse Station, New Jersey, USA